Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NuwellisFRA:22S1 19 Buyback Yield % is -2,075.64 as of Aug. 10, 2026. GuruFocus rates FRA:22S1 with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 344 Medical Devices & Instruments companies, Nuwellis ranks worse than 99.42% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Nuwellis's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:22S1 vs RBOT, ODYY, PFSA: Buyback Yield % Comparison
For the Medical Devices subindustry, Nuwellis's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuwellis Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nuwellis's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Nuwellis's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuwellis (FRA:22S1) has a Buyback Yield % of -2,075.64 as of Aug. 10, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nuwellis and its competitors. According to the industry distribution chart, Nuwellis ranks #342 out of 344 companies in the Medical Devices & Instruments industry, placing it in the top 99.4%.
Is Nuwellis' Buyback Yield % too high?
Nuwellis' current Buyback Yield % is -2,075.64. Based on the distribution chart, Nuwellis ranks #342 out of 344 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nuwellis has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nuwellis' Buyback Yield % compare to RBOT and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nuwellis ranks #342 out of 344 companies for Buyback Yield %. This places Nuwellis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nuwellis and its competitors. Nuwellis's current Buyback Yield % is -2,075.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuwellis stock overvalued right now?
Nuwellis (FRA:22S1) has a current Buyback Yield % of -2,075.64. The current Buyback Yield % is -2,075.64. Nuwellis' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nuwellis (FRA:22S1), the current Buyback Yield % is -2,075.64 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
19GF Score
Get the complete analysis for FRA:22S1
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:22S1 has been successfully added to your 
